

**Meeting of the CDER Antiviral Drugs Advisory Committee**

**March 11, 2005**

**CONSULTANTS AND GUESTS**

***Special Government Employee (SGE) Consultants (voting)***

Samuel K. So, M.B., B.S.  
Professor of Surgery  
Stanford University  
300 Pasteur Drive H3680  
Stanford, California 94305

Kathleen Schwarz, M.D.  
Professor of Pediatrics  
Johns Hopkins University School of Medicine  
600 North Wolfe Street, Brady 320  
Baltimore, Maryland 21287

***Government Employee Consultants (voting)***

Beth P. Bell, M.D., M.P.H.  
Chief, Epidemiology Branch  
Division of Viral Hepatitis  
National Center for Infectious Diseases  
Centers for Disease Control and Prevention  
1600 Clifton Road, NE  
Atlanta, Georgia 30333

Ronald Herbert, D.V.M, Ph.D.  
Veterinary Medical Officer  
National Institutes of Health  
National Institute of Environmental Health  
Sciences  
111 Alexander Drive, Building 101, MD B3-08  
Research Triangle Park, North Carolina 27709

Leonard B. Seeff, M.D.  
Senior Scientist for Hepatitis Research  
National Institutes of Health  
National Institute of Diabetes and Digestive and  
Kidney Diseases  
31A Center Drive, Room 9A27  
Bethesda, Maryland 20817

***SGE Patient Representative (voting)***

Brett Grodeck, Santa Monica, California

---

***FDA Participants at the Table (non-voting)***

Mark J. Goldberger, M.D., M.P.H.  
Director, Office of Drug Evaluation IV, CDER

Debra B. Birnkrant, M.D.  
Director, Division of Antiviral Drug Products, CDER

Katherine A. Laessig, M.D.  
Medical Team Leader, Division of Antiviral Drug Products, CDER

Linda L. Lewis, M.D.  
Medical Officer, Division of Antiviral Drug Products, CDER

James G. Farrelly, Ph.D.  
Pharmacology/Toxicology Team Leader, Division of Antiviral Drug Products, CDER